Sandoz enters agreement for proposed trastuzumab biosimilar, currently in Phase III development, to treat selected HER2-positive cancer tumors

  • Collaboration covers proposed trastuzumab biosimilar in Phase III development for human epidermal growth factor receptor 2 positive (HER2+) breast and gastric tumors
  • Per licence agreement, EirGenix, Inc is responsible for development and manufacturing; Sandoz has right to commercialize in all markets except China and Taiwan
  • Agreement is third announced biosimilars collaboration for Sandoz in 18 months; will build on robust portfolio of eight approved molecules, with a further 10-plus in development

Holzkirchen, Germany, …

/by

Sandoz enters agreement for proposed trastuzumab biosimilar, currently in Phase III development, to treat selected HER2-positive cancer tumors

  • Collaboration covers proposed trastuzumab biosimilar in Phase III development for human epidermal growth factor receptor 2 positive (HER2+) breast and gastric tumors
  • Per licence agreement, EirGenix, Inc is responsible for development and manufacturing; Sandoz has right to commercialize in all markets except China and Taiwan
  • Agreement is third announced biosimilars collaboration for Sandoz in 18 months; will build on robust portfolio of eight approved molecules, with a further 10-plus in development

Holzkirchen, Germany, …

/by

Novartis starts 2019 with strong sales and double digit core[1] operating income growth, Mayzent launch and Alcon spin-off; profit guidance upgraded

  • Transformation to focused medicines company continued with the spin-off of Alcon; commentary below is on continuing operations[2]
  • Continuing operations net sales up 7% (cc[1], +2% USD) driven by Innovative Medicines:
    • Cosentyx was USD 791 million, +41% (cc) with strong demand growth in all indications and regions
    • Entresto grew to USD 357 million, +85% (cc) including the benefit from new data on hospital initiation
    • Oncology sales grew 9% (cc) mainly driven by Lutathera (USD 106 million), Promacta (USD …
/by

Novartis starts 2019 with strong sales and double digit core[1] operating income growth, Mayzent launch and Alcon spin-off; profit guidance upgraded

  • Transformation to focused medicines company continued with the spin-off of Alcon; commentary below is on continuing operations[2]
  • Continuing operations net sales up 7% (cc[1], +2% USD) driven by Innovative Medicines:
    • Cosentyx was USD 791 million, +41% (cc) with strong demand growth in all indications and regions
    • Entresto grew to USD 357 million, +85% (cc) including the benefit from new data on hospital initiation
    • Oncology sales grew 9% (cc) mainly driven by Lutathera (USD 106 million), Promacta (USD …
/by

Sandoz drives differentiated portfolio with deal to commercialize new treatment for Opioid-Induced Constipation in key European countries

  • Agreement with Shionogi to commercialize Rizmoic® (naldemedine) in Germany, UK and Netherlands, plus right of first refusal for certain other European markets
  • Rizmoic® is an innovative medicine for treating constipation caused by opioid pain relief medicines, in patients who have previously been treated with a laxative
  • Agreement reinforces Sandoz anti-pain franchise and commitment to pioneer access to healthcare in areas of unmet medical need

HOLZKIRCHEN, April 11 2019 – Sandoz today announces that it has …

/by

Sandoz drives differentiated portfolio with deal to commercialize new treatment for Opioid-Induced Constipation in key European countries

  • Agreement with Shionogi to commercialize Rizmoic® (naldemedine) in Germany, UK and Netherlands, plus right of first refusal for certain other European markets
  • Rizmoic® is an innovative medicine for treating constipation caused by opioid pain relief medicines, in patients who have previously been treated with a laxative
  • Agreement reinforces Sandoz anti-pain franchise and commitment to pioneer access to healthcare in areas of unmet medical need

HOLZKIRCHEN, April 11 2019 – Sandoz today announces that it has …

/by

Sandoz resubmits biosimilar pegfilgrastim application to US FDA

  • Sandoz pursues US approval for biosimilar pegfilgrastim, a long-acting version of supportive oncology medicine filgrastim
     
  • Pegfilgrastim is used to reduce the incidence of neutropenia, one of the most serious side effects of chemotherapy, hospitalizing 60,000 US cancer patients each year1
     
  • Sandoz is committed to fostering biosimilar competition, to offer high-quality, cost-effective medicines and contribute to a more sustainable healthcare system

Holzkirchen, April 3, 2019 – …

/by